Mini Oral session11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ID 420)
Session NameSpeakers
- Margarita Majem (Barcelona, Spain)
DateFri, 31.03.2023Time08:15 - 09:15RoomAuditorium 1Duration5 Minutes
at the euro congress in 6 weeks
Ann: TACTI-002 data presented at SITC for Efti in 1st line NSCLC, page-7
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |